Fate Therapeutics (FATE) Stock Price, Quote & News

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 875 1800

Website: www.fatetherapeutics.com

Address:

12278 Scripps Summit Drive, San Diego, United States

radonco Nov. 14 at 10:45 PM

$FATE looked through 13F filings…Redmile position unchanged. Something strange I noticed was an investment firm named Wilshire Associates out of Chicago started a new position with 8.4 million shares. This is unusual to me as they don’t own any other bio stocks, have some ETFs, and this is 27% of portfolio…may not be anything but strange nonetheless

1 · Reply

radonco Nov. 14 at 9:32 PM

$FATE big dump in last hour of 1.1M share block…likely dipping lower next week

0 · Reply

murphylaw Nov. 14 at 4:32 PM

$FATE with all big pharmas boosting their pipeline, do not be surprised when not investing in this stock becomes the biggest regret in your life. All it takes is one glorious morning and you see your bank balance explode. Its small caps like these that make instant millionaires.

1 · Reply

Rocketman808 Nov. 14 at 4:12 PM

$FATE some large buys coming in

0 · Reply

Rocketman808 Nov. 14 at 3:35 PM

$FATE ready to buy more if we go lower but we are at the bottom of the channel here, and see the general market rebounding. If im right I will happily buy more at 1.05-1.10 agree with all this is safe with cash on-hand and the r/s comments are laughable. that is a long process and by the time they would need to face that they will have significant data available early next year.

0 · Reply

Southshd Nov. 14 at 3:16 PM

$FATE 210k shares at .95 per share! looking to ad another 15k at .95 today! Is it a black Friday sale today!!

1 · Reply

murphylaw Nov. 14 at 2:09 PM

. $FATE love all the newbies taking about R/S. You dumbasses don't know how to read a balance sheet? You f'ing Walmart workers just focus on bagging groceries than try to be financial analysts. They have 220+ million USD of cash and market cap is 120 million. Safest investment in town!

1 · Reply

noYoav Nov. 14 at 2:33 AM

$FATE It seems there are over 50 more patients treated with FT819 besides those with lupus-related diseases, but the majority of the data disclosed focuses only on the results from the lupus patients, and the significantly larger group of patients in other fields is continuously discussed only regarding safety, without detailed therapeutic results. Does this mean the efficacy in non-lupus patients is almost nonexistent, or am I missing something? I am considering re-entering a position in FATE, and I am concerned about whether they can successfully navigate the risk of a reverse stock split again, given the repeated situation of trading below $1.

0 · Reply

longrigger52 Nov. 13 at 11:01 PM

$FATE the buzzards for circling this pig as it circles the drain……tax loss selling ? perhaps, uncertainty about MOA ? probable

0 · Reply

Adithhya Nov. 13 at 10:01 PM

$FATE congrats to folks who got it under $1! This for me is one of the safest investment in my portfolio! Even If it drops I don’t care! I will buy more cheap ones! Folks never ever sell this stock for a loss pls!

1 · Reply

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 4, 2025, 4:01 PM EST - 10 days ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Oct 26, 2025, 11:30 AM EDT - 19 days ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Aug 12, 2025, 4:01 PM EDT - 3 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jun 11, 2025, 9:00 AM EDT - 5 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

May 30, 2025, 4:30 PM EDT - 6 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 28, 2025, 5:54 PM EDT - 6 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 13, 2025, 4:01 PM EDT - 6 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 8, 2025, 6:22 PM EDT - 6 months ago

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

Apr 29, 2025, 9:25 AM EDT - 7 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 14, 2025, 8:00 AM EDT - 7 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Mar 5, 2025, 4:01 PM EST - 9 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 4, 2025, 4:01 PM EST - 9 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Feb 14, 2025, 4:01 PM EST - 9 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 4, 2025, 7:41 PM EST - 10 months ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 20, 2024, 4:34 PM EST - 1 year ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

May 29, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Mar 19, 2024, 8:44 AM EDT - 1 year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 1, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 8:25 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2023, 12:10 PM EST - 2 years ago

Fate Therapeutics: Getting There, But Perpetually

Nov 8, 2023, 9:12 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

radonco Nov. 14 at 10:45 PM

1 · Reply

radonco Nov. 14 at 9:32 PM

$FATE big dump in last hour of 1.1M share block…likely dipping lower next week

0 · Reply

murphylaw Nov. 14 at 4:32 PM

1 · Reply

Rocketman808 Nov. 14 at 4:12 PM

$FATE some large buys coming in

0 · Reply

Rocketman808 Nov. 14 at 3:35 PM

0 · Reply

Southshd Nov. 14 at 3:16 PM

$FATE 210k shares at .95 per share! looking to ad another 15k at .95 today! Is it a black Friday sale today!!

1 · Reply

murphylaw Nov. 14 at 2:09 PM

1 · Reply

noYoav Nov. 14 at 2:33 AM

0 · Reply

longrigger52 Nov. 13 at 11:01 PM

$FATE the buzzards for circling this pig as it circles the drain……tax loss selling ? perhaps, uncertainty about MOA ? probable

0 · Reply

Adithhya Nov. 13 at 10:01 PM

1 · Reply

longrigger52 Nov. 13 at 8:47 PM

$FATE looks like FATE is about to go on the clock for r/s.....perhaps after r/s they should change the name to FUTILE

1 · Reply

Rocketman808 Nov. 13 at 8:11 PM

$FATE does Sword and Shield technology work against penny land?

1 · Reply

murphylaw Nov. 13 at 6:36 PM

$FATE best deal in town right now. A dollar a share. It's like a black Friday and cyber Monday deal. I loaded up

0 · Reply

Rocketman808 Nov. 13 at 5:31 PM

$FATE

0 · Reply

Rocketman808 Nov. 13 at 2:14 PM

$FATE eps beat, financial discipline is good.

0 · Reply

d_risk Nov. 13 at 1:57 PM

$FATE - Fate Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors FATE’s latest 10-Q flags expanded risks around clinical trial delays, manufacturing scale-up, regulatory hurdles, supply chain disruptions, and reliance on third parties. New risks include manufacturing disruptions, social media missteps, Nasdaq delisting, ESG scrutiny, and geopolitical turmoil, while competition, adverse events, and evolving FDA demands intensify operational and financial uncertainty. #Biotechnology #FDACompliance #CompetitivePressure #GeopoliticalRisk #ESGScrutiny #NasdaqDelisting #SocialMediaRisk #ThirdPartyDependence #SupplyChainDisruptions #RegulatoryChallenges #ManufacturingRisks #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/FATE/10-Q/2025-11-13

0 · Reply

j0nnycash Nov. 13 at 11:09 AM

$FATE when is the earning?

1 · Reply

Jake140 Nov. 13 at 9:53 AM

$FATE Morning All! I just might pick up some more at these prices!

1 · Reply

Rocketman808 Nov. 13 at 2:19 AM

$FATE rebound tomorrow

0 · Reply

Bli1 Nov. 12 at 3:18 PM

$FATE got some yesterday and today. Cheap!

0 · Reply

Bli1 Nov. 12 at 3:15 PM

$CHRS accumulated on 2 cheap bios the last 2 days, $CHRS, $FATE good luck with your picks.

0 · Reply

murphylaw Nov. 12 at 12:50 PM

$FATE where are the earnings?

1 · Reply

Market Cap	119.94M
Revenue (ttm)	13.63M
Net Income (ttm)	-186.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,366.54%
Debt to Equity Ratio	0.00

Volume	2,837,400
Avg Vol	2,369,894
Day's Range	N/A - N/A
Shares Out	115.33M
Stochastic %K	3%
Beta	2.42
Analysts	Sell
Price Target	$4.65